Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
Tango Therapeutics (NASDAQ: TNGX) announced that CEO Barbara Weber, M.D. will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, 4:30–4:55 PM GMT / 11:30–11:55 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tango Therapeutics (NASDAQ: TNGX) announced that CEO Barbara Weber, M.D. will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, 4:30–4:55 PM GMT / 11:30–11:55 AM ET. The session will be available live via webcast under the "Events & Presentations" tab on the company's Investors page. A replay will be archived on the company's website for 90 days after the presentation.
Details
News Market Reaction – TNGX
On Nov 12, the day this news came out, TNGX closed 8.47% below the previous close.
Data tracked by StockTitan Argus for the Nov 12 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, November 19 at 4:30-4:55 PM GMT / 11:30-11:55am ET.
The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.